Adolfo Garcia-Sastre, PhD
img_Adolfo Garcia-Sastre
DIRECTOR GLOBAL HEALTH AND EMERGING PATHOGENS INSTITUTE
PROFESSOR | Microbiology
PROFESSOR | Medicine, Infectious Diseases
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Antivirals, Biodefense, Cellular Immunity, Cytokines, Gene Expressions, Gene Regulation, Gene Therapy, Immune Antagonism, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Interferon Resistance, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, RNA Transport & Localization, Trafficking, Transcription Factors, Transcriptional Activation and Repression, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Immunology [IMM], Microbiology [MIC]
The Garcia-Sastre Laboratory is focused on exploring virus-host interactions with an emphasis on virus regulation of innate and adaptive immune responses. The outcome of these interactions not only determines disease severity but also influences the development of protective immunity resulting from viral infection and/or vaccination. The team has developed several techniques (reverse genetics), which allow for the genetic manipulation of the genomes of several virus families including influenza virus and Newcastle disease virus. Other viruses being studied include Zika virus, Dengue virus, West Nile virus, and Crimean-Congo hemorrhagic fever virus. These techniques are currently being used in several research areas including: i) characterization of virus-encoded virulence factors, ii) identification of virus-encoded antagonists of the interferon system, iii) virus replication and gene expression, iv) immune regulation of influenza replication, and v) vaccine development. Reverse genetics are also being utilized to generate virus vectors based on influenza virus and Newcastle disease virus. These viruses are effective inducers of humoral and cellular immune responses. Live attenuated influenza virus vaccines are being generated by genetic modification of the influenza virus-encoded interferon antagonist that was originally identified by the laboratory. Also, recombinant viruses can be produced that express protective antigens of other pathogens for which no safe attenuated vaccine strains are available.

PhD, University of Salamanca

Publications

Selected Publications

The C-terminal amino acid motifs of NS1 protein affect the replication and virulence of naturally NS-truncated H1N1 canine influenza virus. Pingping Wang, Jianing Guo, Yefan Zhou, Min Zhu, Senbiao Fang, Fanyuan Sun, Chongqiang Huang, Yaohui Zhu, Huabo Zhou, Boyu Pan, Yifeng Qin, Kang Ouyang, Zuzhang Wei, Weijian Huang, Adolfo García-Sastre, Ying Chen. Emerging Microbes and Infections

Evolution of STAT2 resistance to flavivirus NS5 occurred multiple times despite genetic constraints. Ethan C. Veit, Madihah S. Salim, Mariel J. Jung, R. Blake Richardson, Ian N. Boys, Meghan Quinlan, Erika A. Barrall, Eva Bednarski, Rachael E. Hamilton, Caroline Kikawa, Nels C. Elde, Adolfo García-Sastre, Matthew J. Evans. Nature Communications

Monkeypox virus genomic accordion strategies. Sara Monzón, Sarai Varona, Anabel Negredo, Santiago Vidal-Freire, Juan Angel Patiño-Galindo, Natalia Ferressini-Gerpe, Angel Zaballos, Eva Orviz, Oskar Ayerdi, Ana Muñoz-Gómez, Alberto Delgado-Iribarren, Vicente Estrada, Cristina García, Francisca Molero, Patricia Sánchez-Mora, Montserrat Torres, Ana Vázquez, Juan Carlos Galán, Ignacio Torres, Manuel Causse del Río, Laura Merino-Diaz, Marcos López, Alicia Galar, Laura Cardeñoso, Almudena Gutiérrez, Cristina Loras, Isabel Escribano, Marta E. Alvarez-Argüelles, Leticia del Río, María Simón, María Angeles Meléndez, Juan Camacho, Laura Herrero, Pilar Jiménez, María Luisa Navarro-Rico, Isabel Jado, Elaina Giannetti, Jens H. Kuhn, Mariano Sanchez-Lockhart, Nicholas Di Paola, Jeffrey R. Kugelman, Susana Guerra, Adolfo García-Sastre, Isabel Cuesta, Maripaz P. Sánchez-Seco, Gustavo Palacios. Nature Communications

View All Publications

Adolfo Garcia-Sastre, PhD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Garcia-Sastre during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Synairgen
  • Accurius
  • Pfizer Inc.
  • 7 Hills Pharma LLC
  • Avimex
  • Esperovax Inc
  • Applied Biological Laboratories Inc
  • Paratus
  • Pharmamar

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • ContraFect Corporation
  • Vivaldi
  • Amovir
  • Curelab oncology
  • Curelab veterinary
  • Pagoda Genomics

Founder/Co-Founder/Partner

  • Amovir
  • Vaxalto
  • Pagoda Genomics
  • CastleVax Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.